Thursday, 21 August 2003
This presentation is part of : Thursday Poster Sessions

PD-013 Risperidone Improves Psychotic Symptoms in Elderly Patients with Psychosis of Alzheimer’s Disease and Related Dementias

Peter P De Deyn, Laboratory of Neurochemistry and Behavior, University of Antwerp / Born-Bunge Foundation, Antwerp, Belgium, Ira Katz, University of Pennsylvania, Philadelphia, PA, USA, Henry Brodaty, Academic Department for Old Age Psychiatry, Prince of Wales Hospital, Sydney, Australia, Ben Lyons, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Titusville, NJ, USA, and Grant Ko, Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, NJ, USA.

Objective: To study the antipsychotic effects of risperidone versus placebo in treating behavioral and psychological symptoms of dementia (BPSD) in nursing-home residents with psychosis of Alzheimer’s disease and related dementias.

Materials and Methods: Data from three, 12-week, double-blind, placebo-controlled, clinical trials were pooled (n = 1150). The mean risperidone dose in this patient population was 1.0 mg/day. BPSD were evaluated at baseline and at weeks 4, 8 and 12 in a subgroup of patients who were psychotic at baseline [defined as a score of ³2 on any delusion or hallucination item of the Behavioural Pathology in Alzheimer’s Disease (BEHAVE-AD) scale]. Of this population, 687 (59.7%) patients were scored as having baseline psychosis. Patients were randomized to receive either placebo (n=253) or risperidone (n=434). Efficacy was measured using the BEHAVE-AD total and psychotic symptom subscale (combined delusion and hallucination items), and the Clinical Global Impression of Change (CGI-C).

Results: There was no apparent difference between treatment groups in the BEHAVE-AD total baseline scores (mean: 19.7±0.39 and 20.0±0.52 for risperidone and placebo, respectively). A significantly greater improvement was observed for risperidone compared with placebo, beginning at week 4 and continuing throughout treatment (week 8 and 12, P<0.001). The mean reductions from baseline to endpoint in the scores on the BEHAVE-AD psychotic symptom subscale were significantly greater for patients in the risperidone group compared with those in the placebo group (baseline: 7.2 for both groups, mean change from baseline: -3.5±0.21 vs. -2.1±0.32, respectively; P=0.003). For the BEHAVE-AD delusions scale a significant improvement for patients in the risperidone group compared with those in the placebo group was observed (baseline: 5.6 and 5.4, respectively, mean change from baseline: -2.8±017 vs. -1.9±0.25, respectively; P=0.002). No significant changes were observed on the BEHAVE-AD hallucination item (baseline 1.6 and 1.8, respectively, change from baseline -0.7±0.1 vs. -0.6±0.1, respectively; P=0.24), which is probably due to the low baseline scores. The change in CGI-C ratings from baseline to endpoint, as scored by both the investigator and caregiver, indicated a significantly greater improvement in the risperidone-treated group compared with the placebo group (P<0.001 for each). At endpoint investigators (and caregivers) rated 63.6% (61.1%) of risperidone and 43.9% (40.5%) of placebo-treated patients as improved (rating of 1, 2, or 3) and 15.6% (22.3%) of risperidone and 27.3% (36.6%) of placebo-treated patients as worsened (rating of 5, 6, or 7).

Conclusion: Risperidone is effective at low doses in reducing psychotic symptoms in elderly patients with psychosis of Alzheimer’s Disease and related dementias.

Back to PD Thursday Poster Sessions
Back to The Eleventh International Congress